GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Clinical trials for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE explained in plain language.
Never miss a new study
Get alerted when new GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE trials appear
Sign up with your email to follow new studies for GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
MRNA vaccines take on glioblastoma: a new hope against brain cancer recurrence?
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests two mRNA vaccines, GV-907 and GV-108, in 9 adults with a specific type of glioblastoma. The goal is to see if the vaccines are safe and can trigger an immune response to prevent the cancer from coming back after standard treatment.
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: EARLY_PHASE1 • Sponsor: Beijing Neurosurgical Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a common vitamin boost brain cancer treatment?
Disease control TerminatedThis study tests whether adding niacin (vitamin B3) to standard treatment (radiation and chemotherapy) can help people with newly diagnosed glioblastoma, an aggressive brain cancer. The trial has two phases: first, finding a safe dose of niacin, and second, checking if it improve…
Matched conditions: GLIOBLASTOMA IDH (ISOCITRATE DEHYDROGENASE) WILDTYPE
Phase: PHASE1, PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC